{{Refimprove|date=July 2012}}
{{Chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 443990153
| ImageFile = Levosulpiride.svg
| ImageSize = 240
| IUPACName = ''N''-<nowiki>[[</nowiki>(2''S'')-(−)-1-ethylpyrrolidin-2-yl]methyl]-2-methoxy-5-sulfamoylbenzamide
| OtherNames =

|Section1={{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = JTG7R315LK
| IUPHAR_ligand = 958
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = 23672-07-3
| PubChem = 688272
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07312
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 267044
| SMILES = CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 599749
| InChI = 1/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1
| InChIKey = BGRJTUBHPOOWDU-NSHDSACABD
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = BGRJTUBHPOOWDU-NSHDSACASA-N
| RTECS = 
| MeSHName = 
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 4119
 }}

|Section2={{Chembox Properties
| C=15 | H=23 | N=3 | O=4 | S=1
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility = 
 }}

|Section6={{Chembox Pharmacology
| ATCCode_prefix = N05
| ATCCode_suffix = AL07
}}

|Section7={{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt =
 }}
}}

'''Levosulpiride''' is a substituted [[benzamide]] [[antipsychotic]],<ref>{{Cite web|url=http://www.generon.co.uk/amine-oxides-1830/levosulpiride-s-sulpiride-98--231014951.html|title=Levosulpiride - S-(-)-Sulpiride - >98% Generon|last=Generon|website=www.generon.co.uk|access-date=2016-08-31}}</ref> reported to be a selective antagonist of [[Dopamine receptor D2|dopamine D<sub>2</sub> receptor]] activity<ref name=":0">{{Cite web|url=http://www.stratech.co.uk/products/S2104-SEL___levosulpiride|title=Levosulpiride {{!}} Stratech Scientific Ltd|last=http://www.stratech.co.uk/|website=www.stratech.co.uk|access-date=2016-08-31}}</ref> on both [[central nervous system|central]] and [[peripheral nervous system|peripheral]] levels.  It is an atypical [[neuroleptic]] and a [[prokinetic agent]].<ref name=":0" /> Levosulpiride is also claimed to have mood elevating properties. 

Chemically, it is the (''S'')-(−)-[[enantiomer]] of [[sulpiride]].

== Uses ==
Levosulpiride is used in the treatment of:
* [[psychoses]]
* particularly negative symptoms of [[schizophrenia]] 
* [[anxiety]] disorders
* [[dysthymia]]
* [[vertigo]]
* [[dyspepsia]]
* [[irritable bowel syndrome]] 
* [[premature ejaculation]].
Levosulpiride is not currently licensed for treatment of premature ejaculation in the UK or other European countries.<ref>{{Cite journal|last=Poluzzi|first=Elisabetta|last2=Raschi|first2=Emanuel|last3=Koci|first3=Ariola|last4=Moretti|first4=Ugo|last5=Spina|first5=Edoardo|last6=Behr|first6=Elijah R.|last7=Sturkenboom|first7=Miriam|last8=Ponti|first8=Fabrizio De|date=2013-04-04|title=Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database|url=https://link.springer.com/article/10.1007/s40264-013-0032-z|journal=Drug Safety|language=en|volume=36|issue=6|pages=467–479|doi=10.1007/s40264-013-0032-z|issn=0114-5916|pmc=3664739|pmid=23553446}}</ref>

==Side effect ==
Side effects include [[amenorrhea]], [[gynecomastia]], [[galactorrhea]], changes in [[libido]], and [[neuroleptic malignant syndrome]].<ref> http://www.drugsupdate.com/generic/view/860</ref> In the U.S., as of 2013 only one case of adverse reaction to Levosulpiride had been recorded on the FDA Adverse Event Reporting System Database.<ref>{{Cite journal|last=Poluzzi|first=Elisabetta|last2=Raschi|first2=Emanuel|last3=Koci|first3=Ariola|last4=Moretti|first4=Ugo|last5=Spina|first5=Edoardo|last6=Behr|first6=Elijah R.|last7=Sturkenboom|first7=Miriam|last8=Ponti|first8=Fabrizio De|date=2013-04-04|title=Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database|url=https://link.springer.com/article/10.1007/s40264-013-0032-z|journal=Drug Safety|language=en|volume=36|issue=6|pages=467–479|doi=10.1007/s40264-013-0032-z|issn=0114-5916|pmc=3664739|pmid=23553446}}</ref> A case of rapid onset resistant dystonia (involuntary movements of the trunk, lips, and arms) caused by low dose levosulpiride was reported in India.<ref>{{Cite journal|date=2016-08-24|title=Rapid onset resistant dystonia with low dose of Levosulpiride|url=http://bjp.rcpsych.org/content/rapid-onset-resistant-dystonia-low-dose-levosulpiride|language=en}}</ref>

==Mechanism of action==
In contrast to most other neuroleptics which block both dopamine D<sub>1</sub> and D<sub>2</sub> receptors, sulpiride is more selective and acts primarily as a dopamine D<sub>2</sub> antagonist. Sulpiride appears to lack effects on norepinephrine, acetylcholine, serotonin, histamine, or gamma-aminobutyric acid (GABA) receptors. <ref>http://www.drugbank.ca/drugs/DB00391</ref>

==Pharmacodynamics==
Sulpiride is a substituted benzamide derivative and a selective dopamine D<sub>2</sub> antagonist with antipsychotic and antidepressant activity. Other benzamide derivatives include [[metoclopramide]], [[tiapride]], and [[sultopride]].<ref>http://www.drugbank.ca/drugs/DB00391</ref>
	
==References==
{{Reflist|2}}

{{Antipsychotics}}
{{Dopaminergics}}
{{GHBergics}}

[[Category:Typical antipsychotics]]
[[Category:Benzamides]]
[[Category:Enantiopure drugs]]
[[Category:GHB receptor ligands]]
[[Category:Phenol ethers]]
[[Category:Pyrrolidines]]
[[Category:Sulfonamides]]